- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm
- Interventions
- Palbociclib
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 5,442
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Relapsed Solid Tumor Malignancies, Refractory Solid Tumor Malignancies
- Interventions
- IL-12 GEMys, Cyclophosphamide, Fludarabine, Cetuximab
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Advanced Solid Tumor
- Interventions
- Pimasertib, Temsirolimus
- Drug
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Rockland, Massachusetts • Houston, Texas
- Conditions
- Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
- Interventions
- Electronic Health Record Review
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
- Interventions
- Non-Interventional Study
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- KRAS Mutation-Related Tumors, Metastatic Solid Tumor, Advanced Solid Tumor
- Interventions
- TPX-0005, Trametinib
- Drug
- Lead sponsor
- Turning Point Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 6
- States / cities
- California City, California • Denver, Colorado • Nashville, Tennessee + 2 more
- Conditions
- Advanced Solid Tumor
- Interventions
- DB-1310, Trastuzumab, Osimertinib, capecitabine
- Drug
- Lead sponsor
- DualityBio Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 15
- States / cities
- Sacramento, California • Santa Monica, California • Coral Gables, Florida + 12 more
- Conditions
- Solid Tumors, Identified by NGS, PCR or IHC
- Interventions
- Pembrolizumab
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Solid Tumors, Lymphoma
- Interventions
- Alisertib, Esomeprazole, Rifampin
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 7
- States / cities
- Sarasota, Florida • St Louis, Missouri • Oklahoma City, Oklahoma + 4 more
- Conditions
- Solid Tumors
- Interventions
- Olaparib, Pembrolizumab
- Drug · Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 333 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Sacramento, California + 16 more
- Conditions
- Solid Tumors
- Interventions
- OMP-18R5
- Biological
- Lead sponsor
- OncoMed Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 3
- States / cities
- Santa Monica, California • Ann Arbor, Michigan • San Antonio, Texas
- Conditions
- Ewing Sarcoma, Ewing's Sarcoma Recurrent
- Interventions
- Palbociclib, Ganitumab
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 12 Years to 50 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Papillary Thyroid Cancer, Follicular Thyroid Cancer, Huerthle Cell Thyroid Cancer, Renal Cell Carcinoma
- Interventions
- rosiglitazone, XL184
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 5
- States / cities
- Duarte, California • Boston, Massachusetts • The Bronx, New York + 2 more
- Conditions
- Solid Tumors
- Interventions
- Adagrasib, Pembrolizumab, Cetuximab, Pemetrexed, Docetaxel, Irinotecan, Leucovorin, Oxaliplatin, Fluorouracil
- Drug
- Lead sponsor
- Mirati Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Bellflower, California • Long Beach, California + 13 more
- Conditions
- Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
- Interventions
- Biopsy Procedure, Biospecimen Collection, Capecitabine, Carboplatin, Computed Tomography, Durvalumab, Echocardiography Test, Gemcitabine Hydrochloride, Nab-paclitaxel, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Solid Tumor, Advanced Solid Tumor, Solid Tumor, Adult, Metastatic Tumor, Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Metastatic Ovarian Carcinoma, Endometrial Neoplasms, Endometrial Diseases, Metastatic Endometrial Cancer, Triple Negative Breast Cancer, Metastatic Endometrial Carcinoma, Advanced Endometrial Carcinoma, Advanced Ovarian Carcinoma, Gastric Cancer, Advanced Gastric Carcinoma, Metastatic Gastric Cancer, Metastatic Gastric Carcinoma, Small Cell Lung Cancer, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms, Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Carcinoma, CCNE1 Amplification, Hormone Receptor Negative Breast Carcinoma, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Progesterone-receptor-positive Breast Cancer
- Interventions
- NKT3964, Paclitaxel, Doxorubicin
- Drug
- Lead sponsor
- NiKang Therapeutics, Inc.
- Industry
- Eligibility
- 19 Years and older
- Enrollment
- 238 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 19
- States / cities
- Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 16 more
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Crizotinib, Radiologic Examination
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Metastatic Cancer, Pain, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- radiation
- Radiation
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2021
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor, Hepatocellular Carcinoma (HCC), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Head and Neck Squamous Cell Carcinoma (HNSCC), Clear Cell Renal Cell Carcinoma (ccRCC), Non-Clear Cell Renal Cell Carcinoma (nccRCC), Drug-Drug Interaction (DDI)
- Interventions
- Zanzalintinib, Nivolumab, Ipilimumab, Nivolumab + Relatlimab, Prednisone, Docetaxel, DDI Probe Cocktail
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,394 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 46
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Palo Alto, California + 38 more
- Conditions
- Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer, Advanced Solid Tumor, Cutaneous Melanoma, Non-small Cell Lung Cancer
- Interventions
- OR502, Cemiplimab
- Drug
- Lead sponsor
- OncoResponse, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 4
- States / cities
- Austin, Texas • Irving, Texas • San Antonio, Texas + 1 more
- Conditions
- Advanced Solid Tumors
- Interventions
- BMS-986449, Nivolumab
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 4
- States / cities
- Los Angeles, California • New Haven, Connecticut • Hackensack, New Jersey + 1 more
- Conditions
- Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm, Stomatitis
- Interventions
- Anti-inflammatory/Antimicrobial/Analgesic Aqueous Mouth Rinse, Methylene Blue Oral Rinse
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Cancers, SMARCA4 Gene Mutation
- Interventions
- PRT3789, Docetaxel
- Drug
- Lead sponsor
- Prelude Therapeutics Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 20
- States / cities
- Sacramento, California • Santa Monica, California • New Haven, Connecticut + 13 more
- Conditions
- Neoplasms
- Interventions
- PF-06664178
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Aurora, Colorado • Seattle, Washington